Xilio Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$12
Price-to-sales vs peers
Base case. Range ~$12–$91. Sales per share times peers' typical price-to-sales; used only when earnings are negative.
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Xilio Therapeutics, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $64m. Free-cash-flow margin fell to -95.6% from -91.8% a year earlier. Operating margin widened to -48.9% from -377.4%. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $8.45 a share, against a share price of $8.01.
Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Xilio Therapeutics, Inc.'s trailing-twelve-month revenue grew 327.3% year on year, with a free-cash-flow margin of -95.6%.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 345.1% while net income grew 61.2%: a 406pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Xilio Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.87 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$12 ~$26–$91 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$12 ~$12–$91 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Xilio Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2024 | 2025 |
|---|---|---|
| Share price | $13.37 | $8.96 |
| Market value | $51m | $75m |
| + Net debt (− = net cash) | −$55m | −$138m |
| Enterprise value | −$4m | −$63m |
| Multiples | ||
| Price / sales | 8.1x | 1.7x |
| Price / earnings | — | — |
| Price / free cash flow | — | — |
| EV / EBITDA | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.88 | +31% | $40m | −8% |
| Next | −$1.99 | +31% | $50m | +24% |
The consensus EPS forecast for the current fiscal year is −4.6% on 90 days ago. In the last 30 days, 1 analyst raised Xilio Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.02 | −$2.59 |
| 60 days ago | −$2.59 | −$2.23 |
| 30 days ago | −$2.59 | −$2.23 |
| 7 days ago | −$2.59 | −$2.23 |
| Now | −$2.88 | −$1.99 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.59 | −$0.33 | +44.1% |
| Sept 2025 | −$0.42 | −$1.54 | −266.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| XLO | −83% | −80% | +74% | −33% | −11% |
| Industry peers (median) | −56% | −17% | −29% | −5% | −27% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| XLO | 25% | 42% | 50% | 42% | 36% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| XLO | −88% | −88% | −53% | −57% | −30% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 22, 2021: 98% from November 16, 2021 to December 20, 2023. Getting back needed a 4922% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 12, 2026 | −1.9% | +0.9% | +2.5% | −2.7% |
| May 12, 2026 | +0.4% | +0.4% | +5.8% | +3.4% |
| March 23, 2026 | +6.5% | +0.7% | +4.8% | +9.4% |
| January 8, 2026 | −3.5% | +0.7% | −9.2% | −22.6% |
| November 13, 2025 | −8.5% | −1.7% | −3.0% | −15.9% |
| August 14, 2025 | −0.8% | −0.2% | −6.3% | +5.2% |
| May 8, 2025 | +6.4% | +0.6% | +19.9% | +4.9% |
| March 11, 2025 | −2.4% | −0.3% | −8.3% | −19.5% |
| November 7, 2024 | −23.3% | +1.2% | −25.8% | −16.3% |
| August 8, 2024 | +0.6% | +2.8% | −3.7% | −7.2% |
| May 14, 2024 | 0.0% | +1.7% | +7.1% | −6.2% |
| April 1, 2024 | +37.0% | −0.8% | +36.1% | −3.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY25 Q1 | $9.3M |
| FY25 Q2 | $15M |
| FY25 Q3 | $31.8M |
| FY25 Q4 | $43.8M |
| FY26 Q1 | $53.5M |
| FY26 Q2 | $64.1M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY25 Q1 | -614.0% |
| FY25 Q2 | -377.4% |
| FY25 Q3 | -137.6% |
| FY25 Q4 | -95.9% |
| FY26 Q1 | -79.0% |
| FY26 Q2 | -48.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY25 Q2 | -91.8% |
| FY25 Q3 | -55.3% |
| FY25 Q4 | -12.6% |
| FY26 Q1 | -107.3% |
| FY26 Q2 | -95.6% |
| Fiscal year | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|
| Income | |||
| Revenue | 6 | 44 | 64 |
| EBITDA | −59 | −40 | −30 |
| Operating income | −61 | −42 | −31 |
| Net income | −58 | −35 | −22 |
| Diluted EPS | −$15.24 | −$4.19 | — |
| Growth (year on year) | |||
| Revenue | — | +589.9% | +327.3% |
| Margins | |||
| EBITDA margin | −929.0% | −92.4% | −47.0% |
| Operating margin | −954.9% | −95.9% | −48.9% |
| Net margin | −918.0% | −80.1% | −34.1% |
| Free-cash-flow margin | −290.3% | −12.6% | −95.6% |
| Cash flow | |||
| Cash from operations | −18 | −5 | −61 |
| Capital spending | 0 | 1 | 1 |
| Free cash flow | −18 | −6 | −61 |
| Stock-based pay | 6 | 7 | 8 |
| Free cash flow after stock pay | −25 | −12 | −69 |
| Balance sheet | |||
| Cash | 55 | 138 | 136 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −55 | −138 | −136 |
| Diluted shares | 4m | 8m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 2 | 2 | 3 | 8 | 19 | 14 | 13 | 19 |
| EBITDA | −14 | −13 | −13 | −14 | −2 | −12 | −14 | −3 |
| Operating income | −15 | −14 | −14 | −14 | −2 | −12 | −14 | −3 |
| Net income | −14 | −13 | −13 | −16 | −16 | 10 | −10 | −6 |
| Diluted EPS | −$0.22 | −$14.33 | −$2.49 | −$2.30 | −$1.54 | −$3.76 | −$0.58 | −$0.33 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | +243.0% | +742.5% | +693.9% | +331.7% | +131.2% |
| Margins | ||||||||
| EBITDA margin | −634.6% | −768.7% | −455.8% | −172.8% | −8.5% | −84.1% | −108.9% | −17.1% |
| Operating margin | −652.3% | −790.5% | −472.7% | −177.7% | −10.1% | −86.5% | −111.6% | −18.7% |
| Net margin | −619.5% | −759.5% | −452.7% | −196.0% | −85.4% | 75.7% | −75.3% | −34.1% |
| Free-cash-flow margin | −604.6% | −821.5% | 988.3% | −184.0% | −91.8% | −15.3% | −181.0% | −100.5% |
| Cash flow | ||||||||
| Cash from operations | −14 | −14 | 29 | −14 | −17 | −2 | −22 | −19 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | −14 | −14 | 29 | −15 | −17 | −2 | −23 | −19 |
| Stock-based pay | 2 | 2 | 2 | 1 | 1 | 3 | 2 | 2 |
| Free cash flow after stock pay | −15 | −16 | 27 | −16 | −19 | −5 | −25 | −20 |
| Last 12 months unless stated | XLO | CUVL | ABCL | CYTK | RXRX | NTLA | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $64m | $64m | $66m | $68m | $68m | $60m | $58m |
| Revenue growth, last 12 months | 327.3% | 5.2% | 101.3% | −21.1% | 56.2% | 12.6% | 12.7% |
| Revenue growth, 3-year average | — | — | −23.0% | 89.5% | 12.9% | 3.9% | 13.7% |
| Revenue growth, latest quarter | 131.2% | — | −76.3% | −57.1% | 258.5% | −46.2% | 10.2% |
| Gross margin | — | 82.9% | — | — | 29.2% | 100.0% | 82.9% |
| Operating margin | −48.9% | 43.4% | −340.3% | <−999% | −725.4% | −711.7% | −187.2% |
| Operating margin, 3-year average | — | — | −667.5% | <−999% | −995.4% | −940.1% | −363.5% |
| Net margin | −34.1% | 36.0% | −248.8% | <−999% | −697.1% | −672.2% | −163.5% |
| Cash from operations / revenue | −94.5% | 20.1% | −143.5% | −820.8% | −455.1% | −582.5% | −162.3% |
| Free-cash-flow margin | −95.6% | 18.4% | −180.8% | −858.2% | −458.0% | −586.0% | −156.7% |
| Free-cash-flow margin, 3-year average | — | — | −373.0% | <−999% | −664.1% | −738.8% | −310.0% |
| Stock pay / revenue | 12.3% | 2.5% | 77.2% | 188.1% | 129.4% | 114.1% | 19.2% |
| Change in share count | 60.9% | 0.7% | 1.7% | 4.9% | 32.7% | 16.6% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | $6.4M | 664K | 24.1% | 0.0% |
| Orbimed Advisors LLC | $5.7M | 592K | 21.5% | New |
| Frazier Life Sciences Management, L.P. | $4M | 423K | 15.3% | 0.0% |
| Stonepine Capital Management, LLC | $2.2M | 226K | 8.2% | ▲ 252.2% |
| Vanguard Capital Management LLC | $1.7M | 179K | 6.5% | ▲ 44.4% |
| Sio Capital Management, LLC | $1.5M | 152K | 5.5% | 0.0% |
| Adage Capital Partners Gp, L.L.C. | $1.1M | 112K | 4.0% | New |
| Merck & Co., Inc. | $1M | 106K | 3.8% | 0.0% |
| Renaissance Technologies LLC | $614,586 | 64K | 2.3% | ▲ 29.4% |
| Morgan Stanley | $545,619 | 57K | 2.1% | ▼ 0.9% |
| Geode Capital Management, LLC | $374,174 | 39K | 1.4% | ▲ 5.0% |
| Citadel Advisors LLC | $248,601 | 26K | 0.9% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Xilio Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Shannon James Samuel Director | March 26, 2026 | Buy | 5,000 | $8.79 | $43,950 |
| Frankenfield Christopher James Chief Financial Officer | January 2, 2026 | Sell pre-set plan | 7,030 | $0.64 | $4,499 |
| Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | January 2, 2026 | Sell pre-set plan | 1,826 | $0.64 | $1,169 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
